List view / Grid view
29 May 2009 | By
1. How significantly do you feel the Drug Discovery Process has benefited from the application of High Content Analysis techniques? Anthony Davies: Since the mid 1990's High-content analysis (HCA) has primarily been used in the later stages of the pre-clinical drug discovery process. However, as HCA techniques have developed and…
29 May 2009 | By
As the time-to-market of pharmaceutical products has elongated, while its prices are under big pressure, cost saving is currently essential in the pharmaceutical industry.
20 March 2009 | By
Technological advances in robotised microscopy, liquid handling and image processing have enabled the emergence of high content screening where large numbers of specimens are automatically analysed. Here we overview the process discussing potential difficulties and solutions.
There has been a continuous move by the large commercially orientated players involved in Drug Discovery to initiate novel methods to increase income streams and productivity. An example of the former has been the acquisition of companies and their drug pipelines and in the case of the latter, rationalisation of…
7 February 2009 | By
High Content Analysis and Screening technologies (HCA) ushered in a new era in the biomedical research, enabling the scientists to uncover previously unknown disease mechanisms and to introduce innovative approaches to the development of the new generations of therapeutic drugs with a potential to selectively target individual genes, molecules and…
7 February 2009 | By
During the optimisation of drug candidates, improvements in affinity and selectivity play a critical role. This task is usually accomplished by establishing accurate correlations between the affinity/selectivity of different chemical scaffolds and through chemical modifications to a selected scaffold.
7 February 2009 | By
Biotechnological expertise is becoming increasingly important within the pharmaceutical industry, and will play a pivotal role in the monitoring of fermentations, particularly their optimisation within the framework of Process Analytical Technologies (PAT). The ability to harness biological processes for the development of drug therapies, so called ‘biopharmaceuticals’ provides treatments that…
7 February 2009 | By
European Pharmaceutical Review invited four individuals to discuss their views and opinions on current trends and issues surrounding PAT.
10 January 2009 | By
Among the challenges for the pharmaceutical industry, declining research productivity and increasing research costs take a prominent position. This is often put in the context of efforts in the pharmaceutical industry to automate and "industrialise" research activities, combinatorial chemistry and High Throughput Screening being the most prominent examples. An argument…
10 January 2009 | By Martin Warman, Director, MWC Ltd
As the industry approaches the five year anniversary of the ground breaking regulator initiatives (the ‘PAT framework' and ‘cGMPs for the 21st Century'1,2), it is time to assess the impact they have had on the industry and to look forward to what the industry may look like in another five…
3 December 2008 | By
Approximately 45% of all deaths and 50% of all hospitalisations in the western world are a direct result of cardiovascular disease. Cardiomyocyte hypertrophy is a mechanism by which myocardial mass is increased to compensate for any elevated physical demands placed upon the heart, thus ensuring that adequate perfusion of body…
3 December 2008 | By
Last year over 400 thought leaders gathered at the Fifth Annual High-Content Analysis meeting at the San Francisco Fairmont Hotel, on 14-17 January, to discuss the latest technologies and applications in high-content analysis. This year over 400 delegates are expected to attend and over sixty speakers will appear.
3 December 2008 | By
High Throughput Screening (HTS) has for many years now been playing a central role in drug discovery efforts to aid the identification of small molecule chemical entities that are capable of modifying the activity of disease relevant targets1. In order to make HTS a viable option to provide appropriate starting…
3 December 2008 | By
From around the world, a diverse and highly innovative group of academicians, scientists, engineers, post-doctoral associates, graduate students, and business leaders will converge at LabAutomaton2009. The show will be held on 24-28 January 2009, at the Palm Springs Convention Centre, Palm Springs, California.
3 December 2008 | By
Neurotoxicology is not a discipline that can expect to be popular in pharmaceutical circles. It is a not unreasonable prejudice amongst people working in drug development that even a suggestion that a candidate drug might be neurotoxic is enough to halt development, or at the least to stimulate a highly…
